Diagen is the company that currently owns the BPC-157 US patent (the European patent is expired), which was filed in 2012, approved in 2017 with an expected expiration of 2033
The master negative regulator REST/NRSF controls adult neurogenesis by restraining the neurogenic program in quiescent stem cells
A licensed provider reviews your health history, goals, medications, and eligibility before determining whether peptide therapy is appropriate
Liposomal encapsulation offers a solution here: the phospholipids protect the GSH molecule from enzymatic degradation in the gastrointestinal tract, after which absorption takes place partly via endocytosis and lymphatic transport
If you are looking at B12 injections, the most useful starting point is the NHS treatment pathway, because it is built around how the body uses and stores B12 rather than around how often a top-up feels nice to have
Common side effects include mild injection site pain, redness, or swelling